Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.

Abdelrahman, R A; Begna, K H; Al-Kali, A; Hogan, W J; Litzow, M R; Tefferi, A

Abdelrahman, R A; Begna, K H; Al-Kali, A; Hogan, W J; Litzow, M R; Tefferi, A.

Affiliation

Abdelrahman RA; Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Begna KH; Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Al-Kali A; Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Hogan WJ; Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Litzow MR; Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Tefferi A; Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.

Leukemia ; 29(2): 498-500, 2015 Feb.

Article in En | MEDLINE | ID: mdl-25252872

Subject(s)

Benzamides/therapeutic use; Primary Myelofibrosis/therapy; Pyrazoles/therapeutic use; Pyrimidines/therapeutic use; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Follow-Up Studies; Humans; Janus Kinase 2/immunology; Male; Middle Aged; Nitriles; Primary Myelofibrosis/immunology; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Benzamides / Primary Myelofibrosis Type of study: Clinical_trials / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Year: 2015 Document type: Article

Fulltext

XML

PubMed Links

Search on Google